172 related articles for article (PubMed ID: 15077883)
1. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast.
Chan YJ; Chen BF; Chang CL; Yang TL; Fan CC
J Chin Med Assoc; 2004 Jan; 67(1):3-8. PubMed ID: 15077883
[TBL] [Abstract][Full Text] [Related]
2. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
3. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
Kucuk U; Bayol U; Pala EE; Cumurcu S
Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.
Shpitz B; Bomstein Y; Sternberg A; Klein E; Tiomkin V; Kaufman A; Groisman G; Bernheim J
J Surg Oncol; 2002 Feb; 79(2):86-92. PubMed ID: 11815995
[TBL] [Abstract][Full Text] [Related]
5. Patterns of p53 expression in phyllodes tumors of the breast--an immunohistochemical study.
Kim CJ; Kim WH
J Korean Med Sci; 1993 Oct; 8(5):325-8. PubMed ID: 8305139
[TBL] [Abstract][Full Text] [Related]
6. p53 protein expression and gene mutation in phyllodes tumors of the breast.
Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
[TBL] [Abstract][Full Text] [Related]
7. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
8. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases.
Niezabitowski A; Lackowska B; Rys J; Kruczak A; Kowalska T; Mitus J; Reinfuss M; Markiewicz D
Breast Cancer Res Treat; 2001 Jan; 65(1):77-85. PubMed ID: 11245343
[TBL] [Abstract][Full Text] [Related]
9. An approach to malignant mammary phyllodes tumors detection.
Ilić I; Randelović P; Ilić R; Katić V; Milentijević M; Velicković L; Krstić M
Vojnosanit Pregl; 2009 Apr; 66(4):277-82. PubMed ID: 19441158
[TBL] [Abstract][Full Text] [Related]
10. p53 and Ki-67 expression as prognostic factors in cystosarcoma phyllodes.
Erhan Y; Zekioglu O; Ersoy O; Tugan D; Aydede H; Sakarya A; Kapkaç M; Ozdemir N; Ozbal O; Erhan Y
Breast J; 2002; 8(1):38-44. PubMed ID: 11856160
[TBL] [Abstract][Full Text] [Related]
11. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
Esposito NN; Mohan D; Brufsky A; Lin Y; Kapali M; Dabbs DJ
Arch Pathol Lab Med; 2006 Oct; 130(10):1516-21. PubMed ID: 17090194
[TBL] [Abstract][Full Text] [Related]
12. Utility of Ki-67, CD10, CD34, p53, CD117, and mast cell content in the differential diagnosis of cellular fibroadenomas and in the classification of phyllodes tumors of the breast.
Vilela MH; de Almeida FM; de Paula GM; Ribeiro NB; Cirqueira MB; Silva AL; Moreira MA
Int J Surg Pathol; 2014 Sep; 22(6):485-91. PubMed ID: 24492332
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in phyllodes tumor of the breast: are immunohistochemical biomarkers useful?
Chu JS
J Chin Med Assoc; 2004 Jan; 67(1):1-2. PubMed ID: 15077882
[No Abstract] [Full Text] [Related]
14. 2005 Galloway Memorial Lecture: Breast phyllodes tumours--morphology and beyond.
Tan PH
Ann Acad Med Singap; 2005 Dec; 34(11):671-7. PubMed ID: 16453039
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
Jia C; Mei F; Zheng J; You JF; Liu JY
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors.
Koo CY; Bay BH; Lui PC; Tse GM; Tan PH; Yip GW
Mod Pathol; 2006 Oct; 19(10):1344-50. PubMed ID: 16862076
[TBL] [Abstract][Full Text] [Related]
17. Ki67 and P53 Expression in Relation to Clinicopathological Features in Phyllodes Tumour of the Breast.
Mohd Ali NA; Nasaruddin AF; Mohamed SS; Wan Rahman WF
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2653-2659. PubMed ID: 32986365
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical and molecular markers in breast phyllodes tumors.
Korcheva VB; Levine J; Beadling C; Warrick A; Countryman G; Olson NR; Heinrich MC; Corless CL; Troxell ML
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):119-25. PubMed ID: 21030860
[TBL] [Abstract][Full Text] [Related]
19. Phyllodes tumour: cytologic and histologic presentation of 22 cases, and immunohistochemical demonstration of p53.
Shabalova IP; Chemeris GJ; Ermilova VD; Rodionova LM; Pavlikova NA; Syrjänen KJ
Cytopathology; 1997 Jun; 8(3):177-87. PubMed ID: 9202893
[TBL] [Abstract][Full Text] [Related]
20. Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast.
Kang Y; Kim JH; Lee TH; Kim TS; Jung WH; Chung HC; Park BW; Sheen SS; Han JH
Hum Pathol; 2009 Jan; 40(1):98-107. PubMed ID: 18789487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
